Business
Immune Therapeutics, Inc. Announces Appointment of New Director and Acceptance of Election by Director
Immune Therapeutics, Inc. Announces Appointment of New Director and Acceptance of Election by Director.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nImmune Therapeutics, Inc. Announces Appointment of New Director and Acceptance of Election by Director\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nImmune Therapeutics, Inc. Announces Appointment of New Director and Acceptance of Election by Director\nPR Newswire\nORLANDO, Fla. and DUBLIN, Jan. 21, 2015\n\n\n\nORLANDO, Fla. and DUBLIN, Jan. 21, 2015 /PRNewswire/ -- Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, today announced that Vincent Butta, a new director appointed to fill a vacancy, and Edward Teraskiewicz, a director elected at the 2014 Annual Meeting of Shareholders, joined the Board on January 13, 2015. \n\nMs. Noreen Griffin, Chief Executive Officer of Immune Therapeutics, stated, \"We are very excited to bring on these new board members as this allows us to begin to make the changes we promised at our annual meeting. We believe these people bring the changes necessary to advance the company to the next level.\"\n\nVincent Butta was appointed by the Board of Directors on January 13, 2015 to fill a vacancy on the Board. Mr. Butta is a visionary executive business leader with a 30-year track record in Operations, Executive Management, Technology, Supply Chain Management, Marketing, Sales Management, Brand Creation, Licensing, Digital and Social Media, and Strategic Planning. \n\nMr. Butta while President effectively rescued ADC (a worldwide in-store marketing, manufacturing and distribution operation employing 400 people), growing the company from $2 million in negative EBIT to over $117 million in sales and $17 million in EBIT in 4 years. ADC became the largest in-store POP marketing company in the US with over 500,000 square feet of dedicated FDA approved manufacturing and distribution assets employing 400 people worldwide. \n\nMr. Butta was instrumental in the creation and roll out of Sephora ...